BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26854441)

  • 1. An adoptive T cell immunotherapy targeting cancer stem cells in a colon cancer model.
    Gao XY; Wang XL
    J BUON; 2015; 20(6):1456-63. PubMed ID: 26854441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
    Inoda S; Hirohashi Y; Torigoe T; Morita R; Takahashi A; Asanuma H; Nakatsugawa M; Nishizawa S; Tamura Y; Tsuruma T; Terui T; Kondo T; Ishitani K; Hasegawa T; Hirata K; Sato N
    Am J Pathol; 2011 Apr; 178(4):1805-13. PubMed ID: 21435460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and Analysis of Cancer Stem-Like and Non-Cancer Stem-Like Clone Cells from the Human Colon Cancer Cell Line SW480.
    Takaya A; Hirohashi Y; Murai A; Morita R; Saijo H; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Takemasa I; Kondo T; Sato N; Torigoe T
    PLoS One; 2016; 11(7):e0158903. PubMed ID: 27415781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
    Morita R; Hirohashi Y; Torigoe T; Ito-Inoda S; Takahashi A; Mariya T; Asanuma H; Tamura Y; Tsukahara T; Kanaseki T; Kubo T; Kutomi G; Mizuguchi T; Terui T; Ishitani K; Hashino S; Kondo T; Minagawa N; Takahashi N; Taketomi A; Todo S; Asaka M; Sato N
    Clin Cancer Res; 2016 Jul; 22(13):3298-309. PubMed ID: 26861454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma.
    Kano M; Tsukahara T; Emori M; Murase M; Torigoe T; Kawaguchi S; Wada T; Yamashita T; Sato N
    Cancer Sci; 2011 Aug; 102(8):1443-7. PubMed ID: 21518139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.
    Mori T; Nishizawa S; Hirohashi Y; Torigoe T; Tamura Y; Takahashi A; Kochin V; Fujii R; Kondo T; Greene MI; Hara I; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):27-32. PubMed ID: 22001602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
    Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
    Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma.
    Inoda S; Hirohashi Y; Torigoe T; Nakatsugawa M; Kiriyama K; Nakazawa E; Harada K; Takasu H; Tamura Y; Kamiguchi K; Asanuma H; Tsuruma T; Terui T; Ishitani K; Ohmura T; Wang Q; Greene MI; Hasegawa T; Hirata K; Sato N
    J Immunother; 2009 Jun; 32(5):474-85. PubMed ID: 19609239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of side population cells isolated from the colon cancer cell line SW480.
    Xiong B; Ma L; Hu X; Zhang C; Cheng Y
    Int J Oncol; 2014 Sep; 45(3):1175-83. PubMed ID: 24926880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.
    Inoda S; Morita R; Hirohashi Y; Torigoe T; Asanuma H; Nakazawa E; Nakatsugawa M; Tamura Y; Kamiguchi K; Tsuruma T; Terui T; Ishitani K; Hashino S; Wang Q; Greene MI; Hasegawa T; Hirata K; Asaka M; Sato N
    Exp Mol Pathol; 2011 Feb; 90(1):55-60. PubMed ID: 20950610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methyltransferase 1 is essential for initiation of the colon cancers.
    Morita R; Hirohashi Y; Suzuki H; Takahashi A; Tamura Y; Kanaseki T; Asanuma H; Inoda S; Kondo T; Hashino S; Hasegawa T; Tokino T; Toyota M; Asaka M; Torigoe T; Sato N
    Exp Mol Pathol; 2013 Apr; 94(2):322-9. PubMed ID: 23064049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution.
    Kobayashi S; Yamada-Okabe H; Suzuki M; Natori O; Kato A; Matsubara K; Jau Chen Y; Yamazaki M; Funahashi S; Yoshida K; Hashimoto E; Watanabe Y; Mutoh H; Ashihara M; Kato C; Watanabe T; Yoshikubo T; Tamaoki N; Ochiya T; Kuroda M; Levine AJ; Yamazaki T
    Stem Cells; 2012 Dec; 30(12):2631-44. PubMed ID: 23081779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
    Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
    Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.
    Miyamoto S; Kochin V; Kanaseki T; Hongo A; Tokita S; Kikuchi Y; Takaya A; Hirohashi Y; Tsukahara T; Terui T; Ishitani K; Hata F; Takemasa I; Miyazaki A; Hiratsuka H; Sato N; Torigoe T
    Cancer Immunol Res; 2018 Mar; 6(3):358-369. PubMed ID: 29371260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
    Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
    Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting p53 for adoptive T-cell immunotherapy.
    McCarty TM; Liu X; Sun JY; Peralta EA; Diamond DJ; Ellenhorn JD
    Cancer Res; 1998 Jun; 58(12):2601-5. PubMed ID: 9635585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.